The beneficial impact of dexamethasone, acting most likely through its immune-modulating activities, on COVID-19 has been demonstrated [16], and early findings of the REMAP-CAP trial reported a beneficial effect of anti-IL-6R therapy in patients with COVID-19 admitted to the ICU [17]. The gene discussed is IL6R; the disease is COVID-19.